{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:27:04Z","timestamp":1782199624859,"version":"3.54.5"},"reference-count":15,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Ultra rapid lispro (URLi) is a new insulin lispro formulation that has accelerated absorption and improved postprandial glucose control compared with insulin lispro (Humalog\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ). The compatibility and safety of URLi versus lispro were evaluated in patients with type 1 diabetes using continuous subcutaneous insulin infusion (insulin pump).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this phase 3, double-blind, crossover study, 49 patients were randomized to two 6-week treatment periods, after a 2-week lead-in period on lispro. The primary endpoint was the rate of infusion set failures due to a pump occlusion alarm, or unexplained hyperglycemia with blood glucose &gt;13.9\u2009mmol\/L (250\u2009mg\/dL) that did not decrease within 1\u2009h after a correction bolus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There was no significant difference in the rate of infusion set failures between URLi and lispro (0.03 vs. 0.05 events\/30 days,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.375). A higher rate of premature infusion set changes was observed with URLi (1.13 vs. 0.78 events\/30 days;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.028), translating to one additional infusion set change approximately every 3 months. A trend toward improved glycemic control was observed with URLi treatment: Time in range 3.9\u201310.0\u2009mmol\/L (71\u2013180\u2009mg\/dL) was 65.7%\u2009\u00b1\u20091.3% versus 63.0%\u2009\u00b1\u20091.3%. Treatment-emergent adverse events (TEAEs) were reported by 46.9% of patients on URLi treatment and 18.8% on lispro. This difference was driven by an increase in infusion site reactions\u2014more than 90% were mild. Incidence of all other TEAEs and severe hypoglycemia was similar between treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>URLi was compatible with insulin pump use with a safety profile similar to lispro.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2020.0224","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T23:30:27Z","timestamp":1594251027000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study"],"prefix":"10.1177","volume":"23","author":[{"given":"Bruce W.","family":"Bode","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Atlanta Diabetes Associates, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Norwood","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Valley Research, Fresno, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Virgen Macarena, Seville, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hardy","sequence":"additional","affiliation":[{"name":"TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[{"name":"TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Ignaut","sequence":"additional","affiliation":[{"name":"TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","unstructured":"Continuous subcutaneous insulin infusion: Diabetes Care 2004;27(Suppl. 1):S110.","DOI":"10.2337\/diacare.27.2007.S110"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0974-3"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1226"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229681200600402"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1100-P"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1107-P"},{"issue":"4","key":"e_1_3_5_8_2","first-page":"99","article-title":"Greater reduction in postprandial glucose excursions with ultra rapid lispro (URLi) vs lispro in patients with type 1 diabetes at different meal-to-dose timings","volume":"26","author":"Leohr J","year":"2020","unstructured":"Leohr J, , Hoevelmann U, , Dellva M, et al.: Greater reduction in postprandial glucose excursions with ultra rapid lispro (URLi) vs lispro in patients with type 1 diabetes at different meal-to-dose timings. Endocr Pract, 2020; 26(Suppl 4):99.","journal-title":"Endocr Pract"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","unstructured":"Kazda C Leohr J Liu R et al.: Ultra rapid lispro (URLi) shows faster absorption of insulin lispro vs Humalog\u00ae during insulin pump (CSII) use in patients with T1D Diabetes 2018;67:1006-p.","DOI":"10.2337\/db18-1006-P"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229681300700620"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817700545"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817750404"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229680800200314"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/db19-144-OR"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1089-P"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2020.0224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2020.0224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2020.0224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:12:45Z","timestamp":1777399965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2020.0224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1089\/dia.2020.0224"],"URL":"https:\/\/doi.org\/10.1089\/dia.2020.0224","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}